StockData
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT) stock

SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$10.67−1.15 (-9.73%)

Close on Nov 17, 2026Market cap $8.51BP/E –Yield –

Summit Therapeutics EPS

Diluted earnings per share is net income divided by the share count including options and convertible securities.

Summit Therapeutics's EPS for the twelve months ending Jun 30, 2026 was -$1.12. For fiscal 2025 it was -$1.44. The highest annual figure on record is $0.63 in fiscal 2019.

Annual eps

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$1.44–
FY2024Dec 31, 2024-$0.31–
FY2023Dec 31, 2023-$0.99–
FY2022Dec 31, 2022-$0.41–
FY2021Dec 31, 2021-$0.67-206.3%
FY2019Jan 31, 2019$0.63–

Quarterly eps

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$0.28–
Q1 FY2026CQ1 2026Mar 31, 2026-$0.24–
Q4 FY2025CQ4 2025Dec 31, 2025-$0.29–
Q3 FY2025CQ3 2025Sep 30, 2025-$0.31–
Q2 FY2025CQ2 2025Jun 30, 2025-$0.76–
Q1 FY2025CQ1 2025Mar 31, 2025-$0.09–
Q4 FY2024CQ4 2024Dec 31, 2024-$0.08–
Q3 FY2024CQ3 2024Sep 30, 2024-$0.08–
Q2 FY2024CQ2 2024Jun 30, 2024-$0.09–
Q1 FY2024CQ1 2024Mar 31, 2024-$0.06–
Q3 FY2023CQ3 2023Sep 30, 2023-$0.03–
Q2 FY2023CQ2 2023Jun 30, 2023-$0.02–
Q1 FY2023CQ1 2023Mar 31, 2023-$1.43–
Q4 FY2022CQ4 2022Dec 31, 2022-$0.07–
Q3 FY2022CQ3 2022Sep 30, 2022-$0.10–
Q2 FY2022CQ2 2022Jun 30, 2022-$0.12–
Q1 FY2022CQ1 2022Mar 31, 2022-$0.15–
Q4 FY2021CQ4 2021Dec 31, 2021-$0.11–
Q3 FY2021CQ3 2021Sep 30, 2021-$0.20–
Q2 FY2021CQ2 2021Jun 30, 2021-$0.27–
Q1 FY2021CQ1 2021Mar 31, 2021-$0.21–

More Summit Therapeutics figures

See a number that looks wrong?